Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: 4 - The Real Truth

Biogen's Alzheimer's Drug Aduhelm Medicare Coverage Restricted To Just Clinical Trials, CMS Finalizes

Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's (NASDAQ:&

Medicare to pay for Biogen’s Alzheimer’s drug only when used in clinical trials

The U.S. Medicare program finalized a plan to only pay for Biogen Inc.’s Alzheimer’s therapy when it’s used in approved clinical trials, while offering a road map to cover drugs that do show clinical benefit in the disease.

Tribune News Service

Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints

Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints

Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

5 Wildly Undervalued Large-Cap Stocks to Buy Now

Amid current market volatility that is being fueled by investors' anticipation of aggressive interest rate increases this year, rising inflation, economic sanctions on Russia in response to Russia’s invasion of Ukraine, and surging oil prices, investors are seeking investment opportunities in undervalued large-cap companies to generate relatively stable returns. Thus,…

Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab

In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have

Biogen Shares Aduhelm Data In Alzheimer's Disease At 128 Weeks

Biogen Inc (NASDAQ:BIIB) has announced new data from the long-term extension phase of the Phase 3 trials of Aduhelm (aducanumab-avwa) in Alzheimer's disease. The data exhibited that after nearly two and a half years of treatment (128 weeks) with Aduhelm, patients continued to experience significant reductions in two key Alzheimer's disease pathologies, amyloid-beta…

Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact

Eisai Co Ltd (OTC:ESALY) is giving up its right to share in profits from Aduhelm (aducanumab-avwa), which was developed in partnership with Biogen Inc (NASDAQ:BIIB). Biogen and Eisai have amended their agreement to give Biogen full authority to make regulatory and sales decisions regarding Aduhelm. From 2023, Eisai will receive royalties starting at 2% of…

inkl

Read news from The Economist, FT, and more,
with one subscription

Biogen Posts New Updates Across its Spinraza SMA Research Program

Biogen Posts New Updates Across its Spinraza SMA Research Program

Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and NURTURE studies.

Why This Analyst Sees Roughly 20% Upside In This Large-Cap Biopharma

Why This Analyst Sees Roughly 20% Upside In This Large-Cap Biopharma

Biogen Inc (NASDAQ: BIIB) shares are now trading notably off their all-time high of $468.55 hit on June 7, achieved on the back of Aduhel

Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study

Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane

Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have

Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes

Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes

The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc (NASDAQ: BIIB) and its Alzheimer's med, Aduhelm (aducanumab).

Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus

Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus

Biogen Inc (NASDAQ: BIIB) posted Q4 sales of 2.73 billion, beating the consensus of $

Why Biogen Shares Are Sliding Today

Why Biogen Shares Are Sliding Today

Biogen Inc (NASDAQ: BIIB) is trading lower Thursday morning after the company announced worse-than-expected fourth-quarter earnings results and issued guidance below estimates.

Get all your
news in one place.

100's of premium titles.
One news app.

Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab

Biogen Inc (NASDAQ: BIIB) has

Biogen Sells Biosimilar-Venture Stake To Samsung Biologics For $2.3B

Biogen Inc (NASDAQ: BIIB) is selling its stake in a pharmaceutical joint venture with the South Korean conglomerate Samsung for $2.3 billion.

1 2 3 4

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Federal Trade Commission

Securities and Exchange Commission

Cardinal Health Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

416,312 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play